Arne Ring

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan et al. · The Lancet Diabetes & Endocrinology · 2017 · 320 citations

Medicine, Cardiology, Pharmacology +16

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin ^*

Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port et al. · Diabetes Obesity and Metabolism · 2011 · 185 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

Tim Heise, Eva U. Graefe-Mody, S. Hüttner et al. · Diabetes Obesity and Metabolism · 2009 · 175 citations

Medicine, Pharmacokinetics, Pharmacology +16

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul et al. · American Heart Journal · 2013 · 134 citations

Medicine, Endocrinology, Pharmacotherapy +13

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

S. Hüttner, Eva U. Graefe-Mody, B. Withopf et al. · The Journal of Clinical Pharmacology · 2008 · 133 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13